RDHL

RedHill Biopharma Ltd. American Depositary Shares (RDHL) | Rumor.io

RedHill Biopharma

RDHL

Attention (50-day avg)0%

Attention rank (50-day avg)#1,167

Bullish sentiment (50-day avg)79%

Price to earnings ratio0.09

Market capitalization3.1M

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)286K

Net income (annual)-429K

Social

What share of all stock conversation is about RDHL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Sep 2

The warrant overhang is a significant concern for RedHill Biopharma Ltd. ($RDHL), with approximately 18.47M ADS-equivalent shares underlying outstanding warrants, versus only about 6.08M ADSs outstanding, which can create selling pressure and make it harder for the stock to hold higher levels.
The company's cash management issues and history of dilution have been a major problem for RedHill Biopharma Ltd. ($RDHL), but the situation may be different this time if the Ferring deal can generate meaningful and recurring cash flow.
RedHill Biopharma Ltd. ($RDHL) has a small float, and its recent good news has been met with selling pressure, with some investors waiting to see how the company's management executes over the next few months before making a move.

Generated by AI

Sentiment

Of the messages about RDHL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	79.44% +79.44	78.88% -3.13
Bearish	—	—	20.56% -79.44	21.12% +3.13

Bullish· Sep 1

The stock has shown significant price increase, with pre-market gains of ~105.6% and an overall surge of nearly 200%.
Analysts have set a price target of $40.00, indicating a high level of optimism about the company's future performance.
The stock has a low float, which could lead to a large buyout and significant gains for investors who have purchased shares.

Bearish· Aug 31

The company's financials are unattractive, with the need to short sell the only revenue-generating asset to stay afloat.
The company has no products in the near term ready for submission for approval, making it an unappealing investment opportunity.
The company's stock is subject to speculation and manipulation, with multiple posts suggesting that the price is being artificially inflated.

Generated by AI

Topics

Of the messages about RDHL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	45.63%	38.9%
Macro	—	—	16.5%	26.59%
Technical Analysis	—	—	37.86%	9.3%
Analysts	—	—	0%	24.82%
Controversies	—	—	0%	0.39%
Earnings	—	—	0%	0%

Analysts· Aug 31

Cantor Fitzgerald analyst Brandon Folkes initiates coverage on Redhill Biopharma with an Overweight rating and a price target of $22.
The mean estimate from 5 analysts for Redhill Biopharma's Q3 2021 earnings is -$0.16, with a revenue estimate of $27.37M, a $6.43M increase from the same period a year ago.
Analysts polled by Capital IQ have an average rating of buy and price targets ranging from $11.50 to $25 for Redhill Biopharma.

Announcements· Aug 31

RedHill Biopharma Ltd. ($RDHL) has divested its Talicia business to Apotex for $18 million in upfront cash and up to $35 million in potential milestones.
The deal is expected to fuel RedHill's strategic growth opportunities.
The news has caused a significant surge in RedHill's stock price, with $RDHL up 144% premarket.

Controversies· Sep 29

RedHill Biopharma Ltd. (RDHL) has won a major legal victory in a contract dispute, with a New York Supreme Court appeal upholding a $10 million summary judgment against Kukbo.
The court's decision unequivocally dismissed Kukbo's defense, stating that RedHill had fulfilled all obligations in the contract.
RedHill was granted an original award of $8.25 million, plus $1.82 million in legal costs, as the New York court ruled against Kukbo again.

Technical Analysis· Aug 31

The current key level for $RDHL is 1.60, and a potential low is 1.40, with the next target at 1.80.
A pennant is forming on $RDHL, with the current VWAP at $1.56 and the next key level at $1.50, with confirmation requiring volume to break through.
$RDHL needs to hold at $1.50 to confirm a potential bounce, with targets at $1.65, $1.85, $2.00, and $2.25.

Generated by AI

Community

Of the messages about RDHL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	25.06%	30.92%
Newcomers	—	100%	74.94%	69.08%

Regulars· Sep 2

The current share structure, including a large number of outstanding warrants, is a major reason for the stock's struggles to sustain higher prices, with approximately 27M ADS potentially issuable from outstanding warrants as of June 29.
The recent financing and warrant issuance have created a significant warrant overhang, which could lead to selling pressure and make it harder for the stock to hold higher levels when it approaches the $0.70–$0.86 warrant range.
The regulars are cautiously optimistic about the company's prospects, with one noting that the situation may improve over the next few months if the company generates positive catalysts and demand overwhelms the warrant-related supply.

Newcomers· Sep 2

Many users are expecting a significant price increase for RDHL, with some even predicting a price of $1.50 or more.
Newcomers are focusing on the asset's potential for a buyout or merger, with some speculating about the possibility of a deal happening.
Users are also discussing RDHL's recent financial news, including the sale of assets to Apotex and the acquisition of rights to two gastrointestinal drugs, with some analyzing the potential impact on the company's future.

Generated by AI

RedHill Biopharma Ltd. (NASDAQ:RDHL) acquired exclusive global commercialization rights to Rebyota and exclusive U.S. commercialization rights to Clenpiq from Ferring Pharmaceuticals. The agreement has an initial 13-year term and automatically renews for successive two-year periods unless either party elects not to renew. RedHill Biopharma Ltd. (NASDAQ:RDHL) paid $12 million upfront, funded from the $18 million […]

19d agoYahoo Finance

Also Discussed

Investors talking about RDHL also mention

#	Name	Attention
1	Vivos Therapeutics, Inc.VVOS	0%+0
2	PBLA - Panbela Therapeutics, Inc.	——
3	Naya Biosciences Inc.INVO	0%0
4	ParaZero Technologies Ltd.PRZO	0%+0
5	Cardio Diagnostics Holdings, Inc.CDIO	0%0
6	Kamada Ltd.KMDA	0%0
7	BCEL - Atreca, Inc.	——
8	Apollomics Inc.APLM	0%0
9	NEXI - NexImmune, Inc.	——
10	MINM - Minim, Inc.	——

RedHill Biopharma Ltd. American Depositary Shares

Healthcare
Drug Manufacturers - Specialty & Generic

RedHill Biopharma Ltd. American Depositary Shares represent ownership interests in RedHill Biopharma Ltd., a specialty biopharmaceutical company focused on developing and commercializing medicines for gastrointestinal diseases, infectious diseases, and oncology. The company’s current portfolio includes marketed products and clinical-stage programs centered on oral therapies and targeted treatments for adult patients and other specialized medical needs. RedHill Biopharma operates across commercial operations and research and development, combining product sales activities with ongoing clinical advancement. Its business is aimed at addressing areas where treatment options can be limited, making it a participant in the broader specialty pharmaceuticals market. RedHill Biopharma Ltd. is headquartered in Tel Aviv, Israel, and its American Depositary Shares provide U.S. investors with a way to access the company through a depositary share structure.

Website

Location

21 Ha’arba’a Street

Tel Aviv-Yafo, 6473921

Israel

Social

What share of all stock conversation is about RDHL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Sep 2

The warrant overhang is a significant concern for RedHill Biopharma Ltd. ($RDHL), with approximately 18.47M ADS-equivalent shares underlying outstanding warrants, versus only about 6.08M ADSs outstanding, which can create selling pressure and make it harder for the stock to hold higher levels.
The company's cash management issues and history of dilution have been a major problem for RedHill Biopharma Ltd. ($RDHL), but the situation may be different this time if the Ferring deal can generate meaningful and recurring cash flow.
RedHill Biopharma Ltd. ($RDHL) has a small float, and its recent good news has been met with selling pressure, with some investors waiting to see how the company's management executes over the next few months before making a move.

Generated by AI

Sentiment

Of the messages about RDHL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	79.44% +79.44	78.88% -3.13
Bearish	—	—	20.56% -79.44	21.12% +3.13

Bullish· Sep 1

The stock has shown significant price increase, with pre-market gains of ~105.6% and an overall surge of nearly 200%.
Analysts have set a price target of $40.00, indicating a high level of optimism about the company's future performance.
The stock has a low float, which could lead to a large buyout and significant gains for investors who have purchased shares.

Bearish· Aug 31

The company's financials are unattractive, with the need to short sell the only revenue-generating asset to stay afloat.
The company has no products in the near term ready for submission for approval, making it an unappealing investment opportunity.
The company's stock is subject to speculation and manipulation, with multiple posts suggesting that the price is being artificially inflated.

Generated by AI

Topics

Of the messages about RDHL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	45.63%	38.9%
Macro	—	—	16.5%	26.59%
Technical Analysis	—	—	37.86%	9.3%
Analysts	—	—	0%	24.82%
Controversies	—	—	0%	0.39%
Earnings	—	—	0%	0%

Analysts· Aug 31

Cantor Fitzgerald analyst Brandon Folkes initiates coverage on Redhill Biopharma with an Overweight rating and a price target of $22.
The mean estimate from 5 analysts for Redhill Biopharma's Q3 2021 earnings is -$0.16, with a revenue estimate of $27.37M, a $6.43M increase from the same period a year ago.
Analysts polled by Capital IQ have an average rating of buy and price targets ranging from $11.50 to $25 for Redhill Biopharma.

Announcements· Aug 31

RedHill Biopharma Ltd. ($RDHL) has divested its Talicia business to Apotex for $18 million in upfront cash and up to $35 million in potential milestones.
The deal is expected to fuel RedHill's strategic growth opportunities.
The news has caused a significant surge in RedHill's stock price, with $RDHL up 144% premarket.

Controversies· Sep 29

RedHill Biopharma Ltd. (RDHL) has won a major legal victory in a contract dispute, with a New York Supreme Court appeal upholding a $10 million summary judgment against Kukbo.
The court's decision unequivocally dismissed Kukbo's defense, stating that RedHill had fulfilled all obligations in the contract.
RedHill was granted an original award of $8.25 million, plus $1.82 million in legal costs, as the New York court ruled against Kukbo again.

Technical Analysis· Aug 31

The current key level for $RDHL is 1.60, and a potential low is 1.40, with the next target at 1.80.
A pennant is forming on $RDHL, with the current VWAP at $1.56 and the next key level at $1.50, with confirmation requiring volume to break through.
$RDHL needs to hold at $1.50 to confirm a potential bounce, with targets at $1.65, $1.85, $2.00, and $2.25.

Generated by AI

Community

Of the messages about RDHL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	25.06%	30.92%
Newcomers	—	100%	74.94%	69.08%

Regulars· Sep 2

The current share structure, including a large number of outstanding warrants, is a major reason for the stock's struggles to sustain higher prices, with approximately 27M ADS potentially issuable from outstanding warrants as of June 29.
The recent financing and warrant issuance have created a significant warrant overhang, which could lead to selling pressure and make it harder for the stock to hold higher levels when it approaches the $0.70–$0.86 warrant range.
The regulars are cautiously optimistic about the company's prospects, with one noting that the situation may improve over the next few months if the company generates positive catalysts and demand overwhelms the warrant-related supply.

Newcomers· Sep 2

Many users are expecting a significant price increase for RDHL, with some even predicting a price of $1.50 or more.
Newcomers are focusing on the asset's potential for a buyout or merger, with some speculating about the possibility of a deal happening.
Users are also discussing RDHL's recent financial news, including the sale of assets to Apotex and the acquisition of rights to two gastrointestinal drugs, with some analyzing the potential impact on the company's future.

Generated by AI

RedHill Biopharma

Social

Sep 2

Bullish· Sep 1

Bearish· Aug 31

Analysts· Aug 31

Announcements· Aug 31

Controversies· Sep 29

Technical Analysis· Aug 31

Regulars· Sep 2

Newcomers· Sep 2

RedHill (RDHL) Acquires Rebyota and Clenpiq Commercialization Rights for $12M Upfront. Can Sales Outpace Royalties?

12 Health Care Stocks Moving In Monday's Intraday Session

Redhill Biopharma Stock Doubles In One Session — Here's Why

12 Health Care Stocks Moving In Monday's Pre-Market Session

Also Discussed

RedHill Biopharma Ltd. American Depositary Shares

Company Information

Location

RedHill (RDHL) Acquires Rebyota and Clenpiq Commercialization Rights for $12M Upfront. Can Sales Outpace Royalties?

12 Health Care Stocks Moving In Monday's Intraday Session

Redhill Biopharma Stock Doubles In One Session — Here's Why

12 Health Care Stocks Moving In Monday's Pre-Market Session

Also Discussed

Social

Sep 2

Bullish· Sep 1

Bearish· Aug 31

Analysts· Aug 31

Announcements· Aug 31

Controversies· Sep 29

Technical Analysis· Aug 31

Regulars· Sep 2

Newcomers· Sep 2